Showing results (171-180 of 187) with videos related to

Sort By:
Pageof 19
HIV Medicine|November 9, 2010
Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late startersL Waters, M Fisher, J Anderson, et al.
HIV Medicine|November 21, 2008
The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapyC A Sabin, C J Smith, V Delpech, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|June 1, 1996
Pilot study of topical trifluridine for the treatment of acyclovir-resistant mucocutaneous herpes simplex disease in patients with AIDS (ACTG 172). AIDS Clinical Trials GroupH A Kessler, S Hurwitz, C Farthing, et al.
HIV Medicine|November 24, 2011
Non-uptake of highly active antiretroviral therapy among patients with a CD4 count < 350 cells/μL in the UKC Kober, M Johnson, M Fisher, et al.
HIV Medicine|September 8, 2009
Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) StudyR J C Gilson, S-L Man, A Copas, et al.
AIDS Research and Human Retroviruses|June 10, 2005
Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potencyFranco Lori, R B Pollard, L Whitman, et al.
HIV Medicine|May 17, 2011
Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) studyR A Hughes, J A C Sterne, J Walsh, et al.
Neurology|February 23, 2011
Antiretroviral therapy CNS penetration and HIV-1-associated CNS diseaseL Garvey, A Winston, J Walsh, et al.
AIDS (London, England)|April 15, 1999
Ritonavir and saquinavir combination therapy for the treatment of HIV infectionD W Cameron, A J Japour, Y Xu, et al.
HIV Medicine|February 24, 2006
Effects of nandrolone decanoate compared with placebo or testosterone on HIV-associated wastingJ Gold, M J Batterham, H Rekers, et al.
Pageof 19